Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Drew Stein

Sports Medicine Boca Raton, FL Medical Doctor

NPI 1073626024 CMS profile 229636

6853 Sw 18Th St Ste M111, Boca Raton, FL 33433

Open in the dashboard

General payments

$15,257

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Drew Stein of Boca Raton, FL is reported in the CMS Open Payments database as having received $15,257 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2024 General $47 1
2023 General $38 2
2022 General $1,268 4
2021 General $5,858 19
2020 General $131 8
2019 General $7,892 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drew Stein
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Drew Stein were reported at $25. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Drew Stein Sports Medicine median Middle half National median
2019 $7,892 $1,176 $199–$4,249 $163
2020 $131 $708 $96–$2,890 $114
2021 $5,858 $1,213 $152–$3,994 $132
2022 $1,268 $1,230 $159–$3,998 $149
2023 $38 $584 $146–$2,836 $160
2024 $47 $628 $163–$3,168 $164
2025 $25 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $13,179 23 payments
  2. Southern Edge Orthopaedics, Inc. $1,200 1 payment
  3. Horizon Therapeutics plc $429 29 payments
  4. DePuy Synthes Sales Inc. $260 13 payments
  5. Ferring Pharmaceuticals Inc. $89 6 payments
  6. Kowa Pharmaceuticals America, Inc. $38 2 payments
  7. Bioventus LLC $37 2 payments
  8. Vericel Corporation $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,625 6 payments
  2. Travel and Lodging $1,356 11 payments
  3. Education $1,200 1 payment
  4. Food and Beverage $1,076 59 payments
Products named General payments · program years 2019–2025
  1. SpeedSnare $6,750 2 payments
  2. Biowick $6,750 2 payments
  3. Juggerknot $6,750 2 payments
  4. PENNSAID $170 10 payments
  5. VIMOVO Vimovo $161 12 payments
  6. VIMOVO Vimovo $161 12 payments
  7. ORTHOVISC Sports Early Intervention $145 7 payments
  8. CFT $139 2 payments
  9. ORTHOVISC Sports Early Intervention $96 5 payments
  10. EUFLEXXA $89 6 payments
  11. Other $254 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

49

Median for Orthopedic Surgery: 203

Drug cost

$318

Median for Orthopedic Surgery: $1,433

Branded share of claims

24.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 26 $161
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $89
Diclofenac Sodium Generic 11 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$91,488

Of which drugs: $15,690

Medicare patients

264

Average age 76

Services billed

2,283

150 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 41%
Osteoporosis 30%
Diabetes 22%
Depression 19%
Chronic kidney disease 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 46 151 $15,122
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 130 767 $565

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record